Screening Tools for Anxiety in People with Multiple Sclerosis

Litster, Brittany; Fiest, Kirsten M.; Patten, Scott B.; Fisk, John D.; Walker, John R.; Graff, Lesley A; Bolton, James M.; Sareen, Jitender; Marriott, James; Berrigan, Lindsay; Bernstein, Çharles N.; Zarychanski, Ryan; Singer, Alexander; Hitchon, Carol; Peschken, Christine A.; Marrie, Ruth Ann

doi:10.7224/1537-2073.2016-004

Cited by 30 publications

(27 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A recent systematic review of the validity and reliability of anxiety measures found that only the HADS, GAD-7 and BAI had been assessed in MS (Litster et al, 2016); criterion validity of the GAD-7 had not been assessed, and reliability had not been assessed for the HADS or GAD-7. At the proposed cut-points for the general population the sensitivity of the GAD-7 was unacceptably low in our MS population, given that it was designed as a screen specifically for generalized anxiety disorder, while sensitivities for the other measures were modestly better.…”

Section: Discussionmentioning

confidence: 99%

“…A systematic review identified 21 studies which assessed the performance of nine depression screening measures in MS and found that further research was needed to assess the utility of most measures (Hind et al, 2016). A systematic review of screening measures for anxiety found relatively little support for the validity and reliability of three available instruments, the Hospital Anxiety and Depression Scale (HADS), Generalized Anxiety Disorder-7 (GAD-7) and BAI (Litster et al, 2016). Therefore, we aimed to evaluate the validity and reliability of multiple screening measures for depression and anxiety for people with MS.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The validity and reliability of screening measures for depression and anxiety disorders in multiple sclerosis

Marrie

Zhang

Lix

et al. 2018

Multiple Sclerosis and Related Disorders

Self Cite

127

137

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The validity and reliability of screening measures for depression and anxiety disorders in multiple sclerosis

Marrie

Zhang

Lix

et al. 2018

Multiple Sclerosis and Related Disorders

Self Cite

127

137

View full text Add to dashboard Cite

show abstract

“…Whilst several papers have reported good reliability and validity (Maier et al, 1988;Clark and Donvan, 1994;Mondolo et al, 2006;Kummer et al, 2010;Leentjens et al, 2011) with acceptable Cronbach alpha scores were reported in numerous studies (Bjelland et al, 2002;García-Campayo et al, 2012;Chouhan et al, 2016;Erge et al, 2016). However, both Scott et al (2017) and Litster et al (2016) reported little support for the validity and reliability of the HAM-A. The factors structure of the instrument is not standardised, influenced by the medical condition being investigated, ranging from one to a four structure as fitting the data equally well (Bjelland et al, 2002;Leentjens et al, 2011;Cosco et al, 2012;Hung et al, 2015;Scott et al, 2017).…”

Section: Introductionmentioning

confidence: 99%

An Examination of Factor Structure of the Hamilton Anxiety Rating Scale in a Non-Clinical Persian Sample

Slater¹,

Bunting²,

Hasson³

et al. 2019

International Journal of Research in Nursing

View full text Add to dashboard Cite

The Hamilton Anxiety Rating Scale is an internationally used assessment tool for anxiety level however its acceptable factor structure remains fluid. The aim of this paper is to examine the psychometric properties and establish normative anxiety prevalence rates with a Persian randomized sample. A cross sectional survey was distributed to a randomised sample of adults (n = 1260) in the Middle East. A two-factor model was deemed the most statistically and theoretically appropriate measurement model. This represented a split between cognitive and physiological symptoms. Overall, 15.2% of respondents reported at least mild anxiety, with 2.3% experiencing severe anxiety. Lower anxiety scores on the scale were reported among males, the married, younger and higher educated people. The Hamilton Anxiety Scale continues to be a useful tool in the measurement of anxiety. The two factor model separates anxiety into two dimensions, cognitive and physiological aspects and both are highly correlated with each other suggesting a single overarching construct of anxiety. The two-factor model may help provide a better understanding of the effectiveness of different therapeutic techniques. The pooled prevalence of ADs in a non-clinical Persian sample was relatively lower than those of some other countries.

show abstract

“…Therefore, screening tools must be validated in the IMID populations. To date, these validation efforts have been limited to a few tools, and evaluation of psychometric characteristics of these tools has been limited [ 28 - 30 ].…”

Section: Introductionmentioning

confidence: 99%

Effects of Psychiatric Comorbidity in Immune-Mediated Inflammatory Disease: Protocol for a Prospective Study

Marrie¹,

Graff²,

Walker³

et al. 2018

JMIR Res Protoc

Self Cite

View full text Add to dashboard Cite

BackgroundImmune-mediated inflammatory diseases (IMID), such as inflammatory bowel disease (IBD), multiple sclerosis (MS), and rheumatoid arthritis (RA), are highly prevalent in Canada and the United States and result in substantial personal and societal burden. The prevalence of psychiatric comorbidities, primarily depression and anxiety, in IMID exceeds those in the general population by two- to threefold, but remains underdiagnosed and undertreated. Furthermore, the effects of psychiatric comorbidity on IMID are not well understood.ObjectiveThe objectives of this study were (1) to compare health-related quality of life and work ability in persons with IMID and psychiatric comorbidity with those of persons with IMID without psychiatric comorbidity and with those of persons with depression and anxiety disorders alone, and (2) to validate existing case identification tools for depression and anxiety in persons with IMID to facilitate improved identification of depression and anxiety by clinicians. To achieve these objectives, we designed a prospective 3-year longitudinal study. In this paper, we aim to describe the study rationale and design and the characteristics of study participants.MethodsBetween November 2014 and July 2016, we recruited 982 individuals from multiple clinic and community sources; 18 were withdrawn due to protocol violations.ResultsThe final study sample included 247 participants with IBD, 255 with MS, 154 with RA, and 308 with depression or anxiety. The majority were white, with the proportion ranging from 85.4% (IBD [210/246]; MS [217/254]) to 74.5% (114/153, RA; P=.01). There was a female predominance in all groups, which was highest in the RA cohort (84.4%, 130/154) and least marked in the IBD cohort (62.7%, 155/247). Participants with depression or anxiety were more likely to be single (36.0%, 111/308) than participants in any other group (11.8% [30/255]-22.7% [56/247], P<.001).ConclusionsThis paper presents the rationale for this study, describes study procedures, and characterizes the cohort enrolled. Ultimately, the aim is improved care for individuals affected by IMID.

show abstract

Screening Tools for Anxiety in People with Multiple Sclerosis

Abstract: Background: Anxiety is prevalent in people with multiple sclerosis (MS). Screening measures are used to identify symptoms of anxiety, but the optimal measure to screen for anxiety disorders in MS has not been established.

Cited by 30 publications

References 42 publications

The validity and reliability of screening measures for depression and anxiety disorders in multiple sclerosis

The validity and reliability of screening measures for depression and anxiety disorders in multiple sclerosis

An Examination of Factor Structure of the Hamilton Anxiety Rating Scale in a Non-Clinical Persian Sample

Effects of Psychiatric Comorbidity in Immune-Mediated Inflammatory Disease: Protocol for a Prospective Study

Contact Info

Product

Resources

About